Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Golidocitinib + P-GemOx + PD-1 Inhibitor in First-Line Advanced ENKTL
NCT07385989Phase 2Not yet recruiting
- Start
- Jan 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of golidocitinib in Extranodal NK/T-cell lymphoma (ENKTL). Planned start Jan 2026; status: not yet recruiting.
02
Drugs
golidocitinib
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT07385989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07385989.